AAM, Biosimilars Council releases statement on statement on Senate Judiciary Markup of PREVAIL and PERA

The Association for Accessible Medicines and its Biosimilars Council released the following statement concerning the upcoming markup of S. 2220, the PREVAIL Act, and S. 2140, the PERA Act in the Senate Judiciary Committee.

[Read more: AAM, Biosimilar Council host patent abuse Congressional briefing]

"The Association for Accessible Medicines and its Biosimilars Council oppose passage of the PREVAIL Act and the PERA Act. PREVAIL will make it more difficult for generic and biosimilar manufacturers to challenge expensive brand-name drug patent thickets and bring lower-cost medicines to patients, and PERA will enable brand-name drug manufacturers to build even larger thickets and charge higher prices. We call on policymakers to proactively address patent thickets through passage of bipartisan, bicameral legislation such as S. 150, the Affordable Prescriptions for Patients Act, which will help streamline patent litigation and expedite patient access to lower-cost medicine.”

[Read more: AAM report: Generics, biosimilars generate $445B in savings]